Cost-Effectiveness Analysis of PET-CT Surveillance After Treatment of Human Papillomavirus-Positive Oropharyngeal Cancer

Otolaryngol Head Neck Surg. 2024 Jan;170(1):122-131. doi: 10.1002/ohn.483. Epub 2023 Aug 25.

Abstract

Objective: To determine the cost-effectiveness of surveillance imaging with PET/CT scan among patients with human papillomavirus-positive oropharyngeal squamous cell carcinoma.

Study design: Cost-effectiveness analysis.

Setting: Oncologic care centers in the United States with head and neck oncologic surgeons and physicians.

Methods: We compared the cost-effectiveness of 2 posttreatment surveillance strategies: clinical surveillance with the addition of PET/CT scan versus clinical surveillance alone in human papillomavirus-positive oropharyngeal squamous cell carcinoma patients. We constructed a Markov decision model which was analyzed from a third-party payer's perspective using 1-year Markov cycles and a 30-year time horizon. Values for transition probabilities, costs, health care utilities, and their studied ranges were derived from the literature.

Results: The incremental cost-effectiveness ratio for PET/CT with clinical surveillance versus clinical surveillance alone was $89,850 per quality-adjusted life year gained. Flexible fiberoptic scope exams during clinical surveillance would have to be over 51% sensitive or PET/CT scan cost would have to exceed $1678 for clinical surveillance alone to be more cost-effective. The willingness-to-pay threshold at which imaging surveillance was equally cost-effective to clinical surveillance was approximately $80,000/QALY.

Conclusion: Despite lower recurrence rates of human papillomavirus-positive oropharyngeal cancer, a single PET/CT scan within 6 months after primary treatment remains a cost-effective tool for routine surveillance when its cost does not exceed $1678. The cost-effectiveness of this strategy is also dependent on the clinical surveillance sensitivity (flexible fiberoptic pharyngoscopy), and willingness-to-pay thresholds which vary by country.

Keywords: HPV; PET-CT scan; cost-effectiveness; oropharyngeal cancer; surveillance.

MeSH terms

  • Cost-Benefit Analysis
  • Cost-Effectiveness Analysis
  • Head and Neck Neoplasms*
  • Human Papillomavirus Viruses
  • Humans
  • Oropharyngeal Neoplasms* / diagnostic imaging
  • Oropharyngeal Neoplasms* / therapy
  • Positron Emission Tomography Computed Tomography
  • Quality-Adjusted Life Years
  • Squamous Cell Carcinoma of Head and Neck